Loading…
Loading…
INLB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for INLB and 80,000+ other tickers.
See exactly how INLB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for INLB and 80,000+ other tickers.
Based in the United States, Item 9 Labs Corp. operates as a comprehensive cannabis company, encompassing both vertical integration in cannabis operations and the franchising of dispensaries. The firm produces a wide spectrum of cannabis and related goods, such as raw flower, various concentrates, distillates, and necessary hardware. These cannabis and derived technologies and products are then supplied to consumers in Arizona via licensed retail dispensaries. Complementing its production activities, the company also develops and offers medical and adult-use cannabis dispensary franchises under its distinct Unity Rd brand. The main office for Item 9 Labs Corp. is found in Phoenix, Arizona.
Premium Cannabis Product Brand Recognized in Four Categories in Arizona’s Largest Cannabis Awards Program PHOENIX, Nov. 3, 2022 /PRNewswire/ — Item 9 Labs—the award-winning, premium cannabis brand from Item 9 Labs Corp. (OTCQX: INLB)—has officially earned more than 30 podium finishes at Arizona marijuana competitions for product excellence across their high-quality cannabis flower, pre-roll, concentrate and vape products. […]...
Item 9 Labs Corp. (OTCQX:INLB) Q3 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Jason Assad [Abrupt Start] Joining me on today's call is our Chief Executive Officer, Andrew Bowden and our Chief Financial Officer, Bobby Mikkelson. Shortly before this call, we filed our Form 10-Q, a copy of which is available on the company's website at item9labscorp.com.
Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -100% and 29.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PHOENIX , Aug. 3, 2022 /PRNewswire/ -- Item 9 Labs Corp. (OTCQX: INLB) (the "Company")—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that it will host a conference call on Tuesday August 16, 2022, to share financial results for the third quarter of fiscal year 2022, which ended June 30, 2022. The 10Q will be filed on Monday, August 15, 2022.
Item 9 Labs Corp. (OTCQX:INLB) Q2 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Jason Assad - Investor Relations Andrew Bowden - Chief Executive Officer Bobby Mikkelsen - Chief Financial Officer Conference Call Participants Jason Assad Hello, this is Jason Assad, Investor Relations with Item 9 Labs. Good afternoon, and welcome to Item 9 Labs Fiscal Q2 2022 Results Conference Call for the three months ended March 31, 2022.